Last reviewed · How we verify
ABT
ABT is a CTLA-4 modulator Small molecule drug developed by Shanghai Public Health Clinical Center. It is currently FDA-approved for Moderate to severe rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis. Also known as: albuvirtide, any antibiotic therapy.
Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway.
Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway. Used for Moderate to severe rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | ABT |
|---|---|
| Also known as | albuvirtide, any antibiotic therapy |
| Sponsor | Shanghai Public Health Clinical Center |
| Drug class | CTLA-4 modulator |
| Target | CD80/CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Abatacept is a selective, high-affinity inhibitor of the CD80/CD86-CD28 interaction. By blocking this interaction, abatacept reduces the activation of T cells, which are a key component of the immune system. This action helps to decrease the severity of autoimmune diseases such as rheumatoid arthritis.
Approved indications
- Moderate to severe rheumatoid arthritis
- Juvenile idiopathic arthritis
- Psoriatic arthritis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Infections
Key clinical trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia (PHASE2)
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT CI brief — competitive landscape report
- ABT updates RSS · CI watch RSS
- Shanghai Public Health Clinical Center portfolio CI
Frequently asked questions about ABT
What is ABT?
How does ABT work?
What is ABT used for?
Who makes ABT?
Is ABT also known as anything else?
What drug class is ABT in?
What development phase is ABT in?
What are the side effects of ABT?
What does ABT target?
Related
- Drug class: All CTLA-4 modulator drugs
- Target: All drugs targeting CD80/CD86
- Manufacturer: Shanghai Public Health Clinical Center — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate to severe rheumatoid arthritis
- Indication: Drugs for Juvenile idiopathic arthritis
- Indication: Drugs for Psoriatic arthritis
- Also known as: albuvirtide, any antibiotic therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing